JP2000500781A - チエノピリジン誘導体およびHMG―CoAレダクターゼ阻害因子を含む抗血栓症および抗アテローム医薬組成物 - Google Patents
チエノピリジン誘導体およびHMG―CoAレダクターゼ阻害因子を含む抗血栓症および抗アテローム医薬組成物Info
- Publication number
- JP2000500781A JP2000500781A JP10508545A JP50854598A JP2000500781A JP 2000500781 A JP2000500781 A JP 2000500781A JP 10508545 A JP10508545 A JP 10508545A JP 50854598 A JP50854598 A JP 50854598A JP 2000500781 A JP2000500781 A JP 2000500781A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- hydrogen
- pharmaceutically acceptable
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K41/00—Spindle sealings
- F16K41/02—Spindle sealings with stuffing-box ; Sealing rings
- F16K41/04—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing
- F16K41/043—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles
- F16K41/046—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles for rotating valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02D—CONTROLLING COMBUSTION ENGINES
- F02D9/00—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits
- F02D9/04—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits concerning exhaust conduits
- F02D9/06—Exhaust brakes
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K1/00—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces
- F16K1/16—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members
- F16K1/18—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps
- F16K1/22—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps with axis of rotation crossing the valve member, e.g. butterfly valves
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Combustion & Propulsion (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)式: [式中、Rは、水素または(C1−C4)アルコキシカルボニル基である] で示されるチエノピリジン誘導体またはその医薬上許容される塩の一;および (b)HMG−CoAレダクターゼ阻害因子 を含有してなる医薬組成物。 2.成分(a)が活性成分10〜250mgの用量で存在し、成分(b)が活性 成分2〜50mgの用量で存在する請求項1記載の組成物。 3.チエノピリジン誘導体がチクロピジン塩酸塩である請求項1記載の組成物 。 4.単位投与中のチクロピジン塩酸塩の量が100〜250mgである請求項3 記載の組成物。 5.チエノピリジン誘導体がクロピドグレル硫酸水素塩である請求項1記載の 組成物。 6.投与単位中の硫酸水素塩の量が10〜75mg(遊離塩基として計算した) である請求項5記載の組成物。 7.HMG−CoAレダクターゼ阻害因子が (i)式(II): [式中、R1およびR2は、ヒドロキシル基であるか、または、一緒になって酸素 原子を形成し、R3は、(C1−C10)アルキル基、(C3−C10)シクロアルキル基 、(C2−C10)アルケニル基、フェニル基またはフェニル(C1−C3)アルキル基 であり、R4は、水素またはメチル基もくはヒドロキシル基である] で示されるナフタレン誘導体; (ii)R1およびR2がヒドロキシルである式(II)で示される化合物の医薬上許 容される塩; (iii)式(III): [式中、 置換基RoおよびR'のうち一方は、構造式: (式中、Q4は、水素原子、塩素原子もしくはフッ素原子、または(C1−C4)ア ルキル基、(C1−C4)アルコキシ基(t−ブトキシ以外)、トリフルオロメチル 基、フェノキシ基もしくはベンジルオキシ基であり、Q5は、水素原子、塩素原 子もしくはフッ素原子、またはフェノキシ基もしくはベンジルオキシ基であり、 Q5aは、水素原子、塩素原子もしくはフッ素原子、またはメチル基、エチル基、 メトキシ基もしくはエトキシ基である) で示される基であり; 他方の置換基RoおよびR'は、第一または第二(C1−C6)アルキル基、(C3− C6)シクロアルキル基、ベンジル基、2−フェニルエチル基または3−フェニル プロピル基であり; Q2は、水素原子、フッ素原子もしくは塩素原子、または(C1−C4)アルキル 基、(C3−C6)シクロアルキル基、(C1−C4)アルコキシ基(t−ブトキシ以外 )、トリフルオロメチル基、フェノキシ基もしくはベンジルオキシ基であり; Q3は、水素原子、塩素原子もしくはフッ素原子、または(C1−C3)アルキル 基、(C1−C3)アルコキシ基、フェノキシ基もしくはベンジルオキシ基であり; Xは、メチレン基、エチレン基または1,3−プロピレン基であり; Q6は、水素原子または(C1−C3)アルキル基であり; ただし、 (1)R4が水素である場合、Q5およびQ5aは、水素であり、 (2)Q5が水素である場合、Q5aは、水素であり、 (3)Q4およびQ3は、同時には、トリフルオロメチル基、フェノキシ基また はベンジルオキシ基ではなく、 (4)Q2が水素である場合、Q3は、水素であり、 (5)Q2およびQ3は、同時には、トリフルオロメチル基、フェノキシ基また はベンジルオキシ基ではない] で示されるインドール誘導体; (iv)式(III)で示される化合物の医薬上許容されるエステル; (v)式(III)で示される化合物の医薬上許容される塩; (vi)式(III)で示される化合物のδ−ラクトン; (vii)式(IV): [式中、 Q1およびQ1'は、水素、ハロゲン、または(C1−C4)アルキル基、(C1−C4 )アルコキシ基もしくはトリフルオロメチル基であり; Q7、Q7'、Q8およびQ8'は、水素、ハロゲン、または(C1−C4)アルキル基 もしくは(C1−C4)アルコキシ基であり; Q9は、水素、または(C1−C4)アルキル基、(C1−C4)アルコキシアルキル 基もしくは(2−メトキシエトキシ)メチル基である] で示されるテトラゾール誘導体; (viii)式(IV)で示される化合物の医薬上許容される塩; (ix)式(IV)で示される化合物のδ−ラクトン; (x)式(V): で示されるピリジン誘導体; (xi)式(V)で示される化合物の医薬上許容される塩; (xii)式(V)で示される化合物のδ−ラクトン; (xiii)式(VI): で示されるピロール誘導体; (xiv)式(VI)で示される化合物の医薬上許容される塩; (xv)式(VI)で示される化合物のδ−ラクトン から選択される化合物である請求項1記載の組成物。 8.HMG−CoAレダクターゼ阻害因子がシンバスタチン、プラバスタチン ナトリウム、メバスタチン、ロバスタチン、セリバスタチン、アトルバスタチン 、式(III)[式中、Roは、4−フルオロフェニルであり、R'は、イソプロピル であり、Xは、エチレンであり、Q2、Q3およびQ6は、水素である]で示され るラセミもしくは光学活性(E)形のインドール誘導体、該インドール誘導体の医 薬上許容される塩、式(IV)[式中、Q1およびQ2は、各々、フッ素原子であり、 Q7、Q7'、Q8およびQ8'は、水素である]で示される(βR,δS)配置の(E) 形のテトラゾール誘導体、および該テトラゾール誘導体の医薬上許容される塩か ら選択される請求項7記載の組成物。 9.成分(a)がチクロピジン塩酸塩であり、成分(b)がシンバスタチンお よびプラバスタチンナトリウムから選択される請求項2記載の組成物。 10.チクロピジン塩酸塩100〜250mgおよびシンバスタチンまたはプラ バスタチンナトリウム10〜40mgを含有する請求項9記載の組成物。 11.成分(a)クロピドグレル硫酸水素塩であり、成分(b)がシンバスタ チンおよびプラバスタチンナトリウムから選択される請求項2記載の組成物。 12.クロピドグレル硫酸水素塩10〜75mg(遊離塩基として計算した)お よびシンバスタチンまたはプラバスタチンナトリウム10〜40mgを含有する請 求項11記載の組成物。 13.(a)式: [式中、Rは、水素または(C1−C4)アルコキシカルボニル基である] で示されるチエノピリジン誘導体またはその医薬上許容される塩の一;および (b)HMG−CoAレダクターゼ阻害因子 の組合せの抗血栓症薬の製造のための使用。 14.(a)式:[式中、Rは、水素または(C1−C4)アルコキシカルボニル基である] で示されるチエノピリジン誘導体またはその医薬上許容される塩の一;および (b)HMG−CoAレダクターゼ阻害因子 の組合せの抗アテローム薬の製造のための使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609474A FR2751540B1 (fr) | 1996-07-26 | 1996-07-26 | Composition pharmaceutique antithrombotique |
FR96/09474 | 1996-07-26 | ||
PCT/FR1997/001353 WO1998004259A1 (fr) | 1996-07-26 | 1997-07-21 | COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000500781A true JP2000500781A (ja) | 2000-01-25 |
JP3553610B2 JP3553610B2 (ja) | 2004-08-11 |
Family
ID=9494551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50854598A Expired - Fee Related JP3553610B2 (ja) | 1996-07-26 | 1997-07-21 | チェノピリジン誘導体およびHMG―CoAレダクターゼ阻害因子を含む抗血栓症および抗アテローム医薬組成物 |
Country Status (35)
Country | Link |
---|---|
US (1) | US6218403B1 (ja) |
EP (1) | EP0914124B1 (ja) |
JP (1) | JP3553610B2 (ja) |
KR (1) | KR100307268B1 (ja) |
CN (1) | CN1109547C (ja) |
AR (1) | AR008782A1 (ja) |
AT (1) | ATE258052T1 (ja) |
AU (1) | AU725949B2 (ja) |
BR (1) | BR9710560B1 (ja) |
CA (1) | CA2261099C (ja) |
CZ (1) | CZ294664B6 (ja) |
DE (1) | DE69727299T2 (ja) |
DK (1) | DK0914124T3 (ja) |
EE (1) | EE03853B1 (ja) |
ES (1) | ES2214632T3 (ja) |
FR (1) | FR2751540B1 (ja) |
HK (1) | HK1019405A1 (ja) |
HU (1) | HU226245B1 (ja) |
ID (1) | ID17774A (ja) |
IL (1) | IL128102A0 (ja) |
IS (1) | IS2052B (ja) |
MY (1) | MY125051A (ja) |
NO (1) | NO322894B1 (ja) |
NZ (1) | NZ333826A (ja) |
PL (1) | PL188739B1 (ja) |
PT (1) | PT914124E (ja) |
RS (1) | RS49504B (ja) |
RU (1) | RU2176504C2 (ja) |
SI (1) | SI0914124T1 (ja) |
SK (1) | SK284944B6 (ja) |
TR (1) | TR199900154T2 (ja) |
TW (1) | TW442289B (ja) |
UA (1) | UA58518C2 (ja) |
WO (1) | WO1998004259A1 (ja) |
ZA (1) | ZA976247B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2769313B1 (fr) * | 1997-10-06 | 2000-04-21 | Sanofi Sa | Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese |
US7141602B2 (en) * | 1998-09-18 | 2006-11-28 | Lek Pharmaceuticals D.D. | Process for obtaining HMG-CoA reductase inhibitors of high purity |
IL162461A0 (en) * | 2001-12-18 | 2005-11-20 | Teva Pharma | Polymorphs of clopidogrel hydrogensulfate |
US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
ATE482698T1 (de) * | 2003-06-18 | 2010-10-15 | Inst Cardiologie De Montreal M | Vermeidung von vorhofflimmern (af) mit der verwendung von statin |
US6978908B2 (en) * | 2003-09-15 | 2005-12-27 | Gerber Products Company | Drinking vessel with adjustable handles |
KR100563455B1 (ko) * | 2004-04-09 | 2006-03-23 | 한미약품 주식회사 | 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물 |
US8580818B2 (en) * | 2005-09-15 | 2013-11-12 | Otsuka Pharmaceutical Co., Ltd. | Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
KR101784001B1 (ko) * | 2006-04-04 | 2017-10-23 | 케이지 액퀴지션 엘엘씨 | 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물 |
US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
CA2655844A1 (en) * | 2006-08-03 | 2008-02-14 | Teva Pharmaceutical Industries Ltd. | Process for preparing clopidogrel bisulphate |
WO2008060934A2 (en) * | 2006-11-14 | 2008-05-22 | Acusphere, Inc. | Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration |
RU2009140792A (ru) * | 2007-04-09 | 2011-05-20 | Юсв Лимитед (In) | Новые стабильные фармацевтические композиции клопидогрель бисульфата и способ их получения |
EP2148655B1 (en) * | 2007-04-20 | 2013-02-27 | Wockhardt Limited | Pharmaceutical compositions of clopidogrel |
KR20160033792A (ko) * | 2007-04-27 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법 |
WO2010009745A1 (en) * | 2008-07-25 | 2010-01-28 | Pharmathen S.A. | Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
NZ597510A (en) | 2009-06-25 | 2012-12-21 | Tetra Sia | NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium |
RU2461379C2 (ru) * | 2010-12-09 | 2012-09-20 | Закрытое акционерное общество "ФАРМ-ЦЕНТР" (ЗАО "ФАРМ-ЦЕНТР") | Фармацевтическая комбинация, обладающая антиагрегантной и липидрегулирующей активностями, фармацевтическая композиция |
BR112019015107A2 (pt) | 2017-01-23 | 2020-03-10 | Dong Wha Pharm. Co., Ltd. | Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
FR2665440B1 (fr) * | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
WO1995011898A1 (en) * | 1992-05-12 | 1995-05-04 | Nissan Chemical Industries Ltd. | Condensed pyridine type mevalonolactone intermediate and process for its production |
AU1095695A (en) * | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
-
1996
- 1996-07-26 FR FR9609474A patent/FR2751540B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-15 ZA ZA976247A patent/ZA976247B/xx unknown
- 1997-07-15 TW TW086110010A patent/TW442289B/zh not_active IP Right Cessation
- 1997-07-18 AR ARP970103243A patent/AR008782A1/es active IP Right Grant
- 1997-07-21 PL PL97331339A patent/PL188739B1/pl unknown
- 1997-07-21 SI SI9730622T patent/SI0914124T1/xx unknown
- 1997-07-21 CA CA002261099A patent/CA2261099C/fr not_active Expired - Fee Related
- 1997-07-21 EE EEP199900028A patent/EE03853B1/xx not_active IP Right Cessation
- 1997-07-21 HU HU9903752A patent/HU226245B1/hu not_active IP Right Cessation
- 1997-07-21 TR TR1999/00154T patent/TR199900154T2/xx unknown
- 1997-07-21 AU AU38526/97A patent/AU725949B2/en not_active Ceased
- 1997-07-21 DE DE69727299T patent/DE69727299T2/de not_active Expired - Lifetime
- 1997-07-21 UA UA99021085A patent/UA58518C2/uk unknown
- 1997-07-21 RU RU99103623/14A patent/RU2176504C2/ru not_active IP Right Cessation
- 1997-07-21 US US09/230,299 patent/US6218403B1/en not_active Expired - Lifetime
- 1997-07-21 JP JP50854598A patent/JP3553610B2/ja not_active Expired - Fee Related
- 1997-07-21 RS YU3199A patent/RS49504B/sr unknown
- 1997-07-21 BR BRPI9710560-0B1A patent/BR9710560B1/pt not_active IP Right Cessation
- 1997-07-21 EP EP97935593A patent/EP0914124B1/fr not_active Expired - Lifetime
- 1997-07-21 WO PCT/FR1997/001353 patent/WO1998004259A1/fr active IP Right Grant
- 1997-07-21 IL IL12810297A patent/IL128102A0/xx not_active IP Right Cessation
- 1997-07-21 PT PT97935593T patent/PT914124E/pt unknown
- 1997-07-21 NZ NZ333826A patent/NZ333826A/xx not_active IP Right Cessation
- 1997-07-21 CN CN97197539A patent/CN1109547C/zh not_active Expired - Fee Related
- 1997-07-21 SK SK78-99A patent/SK284944B6/sk not_active IP Right Cessation
- 1997-07-21 AT AT97935593T patent/ATE258052T1/de active
- 1997-07-21 ES ES97935593T patent/ES2214632T3/es not_active Expired - Lifetime
- 1997-07-21 CZ CZ1999176A patent/CZ294664B6/cs not_active IP Right Cessation
- 1997-07-21 DK DK97935593T patent/DK0914124T3/da active
- 1997-07-24 ID IDP972577A patent/ID17774A/id unknown
- 1997-07-25 MY MYPI97003383A patent/MY125051A/en unknown
-
1999
- 1999-01-22 IS IS4951A patent/IS2052B/is unknown
- 1999-01-22 KR KR1019997000501A patent/KR100307268B1/ko not_active IP Right Cessation
- 1999-01-25 NO NO19990321A patent/NO322894B1/no not_active IP Right Cessation
- 1999-11-01 HK HK99104578A patent/HK1019405A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000500781A (ja) | チエノピリジン誘導体およびHMG―CoAレダクターゼ阻害因子を含む抗血栓症および抗アテローム医薬組成物 | |
US20040126423A1 (en) | Pharmaceutical formulation | |
MXPA03005883A (es) | Composiciones farmaceuticas que comprenden maleato de amlodipina. | |
FR2900823A1 (fr) | Nouvelle forme d'administration du racecadotril. | |
BE1000661A4 (fr) | Nouvelles compositions pharmaceutiques a base de ketotifene. | |
EP1663174A1 (en) | Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent | |
FR2977495A1 (fr) | Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation | |
EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
TWI725442B (zh) | 包含西洛他唑及他汀衍生物的醫藥組合物 | |
TWI697339B (zh) | 醫藥製劑 | |
JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
JPS6241500B2 (ja) | ||
JP2009234946A (ja) | 併用医薬 | |
RU2545833C1 (ru) | Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения | |
MXPA99000800A (es) | Composicion farmaceutica antitrombotica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040430 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100514 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120514 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |